BI 2536, a selective inhibitor of polo-like kinase 1 (PLK1) (50), has been used in several clinical trials as a treatment for patients with AML (Clinicaltrials.gov: NCT00701766) and non-small-cell lung cancer (Clinicaltrials.gov: NCT02211833). Here, PLK1 is linked to non-small cell lung carcinoma.